# Akari Therapeutics (AKTX) — News

AKTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/aktx/news

## Recent headlines

- [PLC Resources Ltd - Geo-spectral survey commences at Abbotts Gold project, WA](https://www.ainvest.com/news/plc-resources-geo-spectral-survey-commences-abbotts-gold-project-wa-2610) — AInvest Wire, Oct 13, 2026
  PLC Resources Ltd (ASX: PLC) has announced the commencement of a geo-spectral survey at its Abbotts Gold project in Western Australia. The survey is part of the company’s ongoing exploration efforts to identify potential gold-bearing structures within the project area. Geo-spectral surveys utilise…
- [Akari Therapeutics appoints accomplished oncology and ADC deal executive Vatak Vat-Ho as chief business officer to drive strategic growth and partnering](https://www.ainvest.com/news/akari-therapeutics-appoints-accomplished-oncology-adc-deal-executive-vatak-vat-ho-chief-business-officer-drive-strategic-growth-partnering-2610) — AInvest Wire, Oct 13, 2026
- [Akari Therapeutics expands intellectual property portfolio with PCT filing for ADC payload related to RNA splicing in cancers](https://www.ainvest.com/news/akari-therapeutics-expands-intellectual-property-portfolio-pct-filing-adc-payload-related-rna-splicing-cancers-2610) — AInvest Wire, Oct 1, 2026
  Akari Therapeutics has expanded its intellectual property portfolio by filing a Patent Cooperation Treaty (PCT) application for an antibody-drug conjugate (ADC) payload related to RNA splicing in cancers. This development follows recent patent grants in Europe and Australia for ADC technologies,…
- [Akari Therapeutics enters strategic research collaboration with Whitehawk Therapeutics](https://www.ainvest.com/news/akari-therapeutics-enters-strategic-research-collaboration-whitehawk-therapeutics-2607) — AInvest Wire, Jul 21, 2026
- [Akari Therapeutics PLC: Maxim Group raises to buy from hold](https://www.ainvest.com/news/akari-therapeutics-plc-maxim-group-raises-buy-hold-2607) — AInvest Wire, Jul 20, 2026
  Maxim Group has upgraded its rating for Akari Therapeutics PLC (AKTX), moving from "Hold" to "Buy," reflecting a positive shift in the firm's outlook for the biopharmaceutical company. The decision follows recent developments in Akari's clinical pipeline and strategic initiatives aimed at advancing…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).